| Literature DB >> 30100899 |
Luan L Chu1, Dipesh Dhakal1, Hee J Shin1, Hye J Jung1,2, Tokutaro Yamaguchi2, Jae K Sohng1,2.
Abstract
Flavonoids are one of the predominant groups of plant polyphenols, and these compounds have significant effects on human health and nutrition. Sulfated flavonoids have more favorable attributes compared to their parent compounds such as increased solubility, stability, and bioavailability. In this research, we developed a microbial system to produce sulfated naringenin using Escherichia coli expressing a sulfotransferase (ST) from Arabidopsis thaliana (At2g03770). This wild-type strain was used as a model system for testing clustered regularly interspaced short palindromic repeats (CRISPR) interference (CRISPRi) metabolic engineering strategies. Using synthetic sgRNA to mediate transcriptional repression of cysH, a gene encoding 3'-phosphoadenosine-5'-phosphosulfate (PAPS) ST, which is involved in sulfur metabolism, resulted in an increase in intracellular PAPS accumulation by over 3.28-fold without impairing cell growth. Moreover, naringenin 7-sulfate production by engineering E. coli with its cysH gene repressed in the open reading frame through CRISPRi was enhanced by 2.83-fold in compared with the wild-type control. To improve the efficiency of biotransformation, the concentration of SO42- , glucose, and substrate were optimized. The bioproductivity of naringenin 7-sulfate was 135.49 μM [∼143.1 mg (47.7 mg L-1)] in a 3-L fermenter at 36 h. These results demonstrated that the CRISPRi system was successfully applied for the first time in E. coli to develop an efficient microbial strain for production of a sulfated flavonoid. In addition, antibacterial and anticancer activities of naringenin 7-sulfate were investigated and found to be higher than the parent compound.Entities:
Keywords: CRISPRi; E. coli; PAPS; metabolic engineering; sulfotransferase
Year: 2018 PMID: 30100899 PMCID: PMC6072979 DOI: 10.3389/fmicb.2018.01671
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Strains and plasmids used in this study.
| Strain/plasmids | Properties/genotype | Source/reference |
|---|---|---|
| F-Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK-, mK+) phoA supE44 λ- thi-1 gyrA96 relA1 | Novagen | |
| ompT hsdT hsdS (rB- mB-) gal (DE3) | Novagen | |
| Wild-type | This study | |
| S1 | This study | |
| S2 | This study | |
| Plasmid vectors | ||
| pET 28a(+) | Expression vector with T7 promoter, p15A ori, Kmr | Novagen |
| pET 28a(+)-At3g45070 | pET 28a(+) carrying At2g03770 from | This study |
| pCRISPathBrick | pACYC184 (Cmr), p15A ori, | |
| CRISPRi-1 | pCRISPathBrick, CRISPR spacer targeting | This study |
| CRISPRi-2 | pCRISPathBrick, CRISPR spacer targeting | This study |
Inhibition zone diameter (mm) of naringenin and naringenin 7-sulfate against nine Gram-positive bacteria and six Gram-negative bacteria.
| No. | Pathogens | Naringenin | Naringenin 7-sulfate | Ampicillin |
|---|---|---|---|---|
| 1 | – | 7.0 ± 0.08 | 7.2 ± 0.09 | |
| 2 | – | + | + | |
| 3 | – | + | 23 ± 0.27 | |
| 4 | – | + | 20 ± 0.24 | |
| 5 | – | 9.5 ± 0.18 | 15 ± 0.36 | |
| 6 | – | – | – | |
| 7 | – | – | – | |
| 8 | – | – | 13 ± 0.18 | |
| 9 | – | – | 14 ± 0.20 | |
| 10 | – | – | 16 ± 0.14 | |
| 11 | – | – | 16 ± 0.12 | |
| 12 | – | – | 30 ± 0.32 | |
| 13 | + | + | 13 ± 0.14 | |
| 14 | – | 7.2 ± 0.12 | – | |
| 15 | – | + | 9 ± 0.10 | |